Search

PRESTO was established in 2022 and is a concerted effort by leading European experts in the field of P2XRs and extracellular ATP to promote and advance the transition to the clinic of P2XR-targeting therapies. Following the inaugural meeting in Ferrara which set the foundations of the action and generated interest from many groups and institutes, the second meeting covered the preclinical and clinical aspects of P2XRs as a common route in different diseases, recognising the multidisciplinary and collaborative approach required for a number of medical conditions. [ABSTRACT FROM AUTHOR]

The inaugural meeting of the EU COST Action CA21130 PRESTO was held in February 2023, at the University of Ferrara, Italy. Our meeting report provides an overview of PRESTO, a tribute to Professor Jim Wiley, overviews of the talk, and a speaker synopsis that discusses the resources, models, equipment, and techniques available in different lab groups throughout Europe, increasing the prospect of collaborative research. [ABSTRACT FROM AUTHOR]

This paper examines two sustainability practices in complex and uncertain processes such as the case of the promotion of the underground built heritage (UBH). Convinced that the sustainability of a UBH valorisation project is only guaranteed by its survival over time, the authors argue that the decision-making process must be bottom-up, i.e., promoted and developed by the actors of the territory—communities and stakeholders—who share a strategic objective. They assume that they have already defined the value of the asset to be enhanced through heritage interpretation. At this point, two practices are proposed. The first is aimed at enhancing the UBH for the territory itself and involves the application of design thinking; the second, in the interest of the economic agents, is aimed at promoting the territory externally—promoting sustainable tourism—through the application of audience development. The work is a theoretical proposal and has not yet been tested in the field. The authors reserve the right to test it in a subsequent case study. [ABSTRACT FROM AUTHOR]

The key goal in biomedical research is a better understanding of disease aetiologies, which ideally results in strategies and recommendations for the prevention of diseases before they arise, and in the development of effective therapies. However, many concerns have been expressed about the reproducibility and the translational validity of preclinical research in animal models to inform clinical trials in humans. It has been proposed that improving internal, external and construct validity of animal studies will lead to improved translatability. Automated behaviour monitoring in the animal's home cage, which allows for longitudinal assessment of individual trajectories over sufficiently long intervals for (chronic) drug treatment or phenotype progression, is a promising solution to these problems. [ABSTRACT FROM AUTHOR]

We present work of our COST Action on "Understanding and exploiting the impacts of low pH on micro-organisms". First, we summarise a workshop held at the European Federation of Biotechnology meeting on Microbial Stress Responses (online in 2020) on "Industrial applications of low pH stress on microbial bio-based production", as an example of an initiative fostering links between pure and applied research. We report the outcomes of a small survey on the challenging topic of developing links between researchers working in academia and industry that show that, while people in different sectors strongly support such links, barriers remain that obstruct this process. We present the thoughts of an expert panel held as part of the workshop above, where people with experience of collaboration between academia and industry shared ideas on how to develop and maintain links. Access to relevant information is essential for research in all sectors, and because of this we have developed, as part of our COST Action goals, two resources for the free use of all researchers with interests in any aspects of microbial responses to low pH. These are (1) a comprehensive database of references in the literature on different aspects of acid stress responses in different bacterial and fungal species, and (2) a database of research expertise across our network. We invite the community of researchers working in this field to take advantage of these resources to identify relevant literature and opportunities for establishing collaborations. • Summary of workshop on "Industrial applications of low pH stress on microbial bio-based production". • Summary of survey and discussion section on barriers to developing effective academic-industrial collaborations. • Database of papers discussing mechanistic aspects of acid stress responses in diverse bacteria and fungi. • Database of expertise in COST Action CA18113. [ABSTRACT FROM AUTHOR]

This article reviews the European Network for Combining Language Learning with Crowdsourcing Techniques (enetCollect), an extensive network project created to foster research and innovation (R&I) on the combination of crowdsourcing and language learning. Accordingly, we explain how it began, introduce its overall logic and organization, and discuss its achievements in terms of both (1) creating a new R&I community through a concluded large network project, and (2) fostering R&I on a high-potential and mostly unexplored subject. We also discuss the challenges involved and lessons learned, whether in orchestrating and leading a new R&I community or the challenges we faced and generally observed in the efforts of enetCollect members, as they explored the many facets of such a versatile enterprise.

This Community Resource paper introduces the range of materials developed by the INDEPTH (Impact of Nuclear Domains on Gene Expression and Plant Traits) COST Action made available through the INDEPTH Academy. Recent rapid growth in understanding of the significance of epigenetic controls in plant and crop science has led to a need for shared, high-quality resources, standardization of protocols, and repositories for open access data. The INDEPTH Academy provides a range of masterclass tutorials, standardized protocols, and teaching webinars, together with a rapidly developing repository to support imaging and spatial analysis of the nucleus and deep learning for automated analysis. These resources were developed partly as a response to the COVID-19 pandemic, but also driven by needs and opportunities identified by the INDEPTH community of ~200 researchers in 80 laboratories from 32 countries. This community report outlines the resources produced and how they will be extended beyond the INDEPTH project, but also aims to encourage the wider community to engage with epigenetics and nuclear structure by accessing these resources. [ABSTRACT FROM AUTHOR]

Proteins are essential molecular actors in every cellular process. From their synthesis to their degradation, they are subject to continuous quality control mechanisms to ensure that they fulfil cellular needs in proper and timely fashion. Proteostasis is a key process allowing cells or organisms to maintain an appropriate but dynamic equilibrium of their proteome (the ensemble of all their proteins). It relies on multiple mechanisms that together control the level, fate and function of individual proteins, and ensure elimination of abnormal ones. The proteostasis network is essential for development and adaptation to environmental changes or challenges. Its dysfunctions can lead to accumulation of deleterious proteins or, conversely, to excessive degradation of beneficial ones, and are implicated in many diseases such as cancers, neurodegeneration, or developmental and aging disorders. Manipulating this network to control abundance of selected target proteins is therefore a strategy with enormous therapeutic or biotechnological potential. The ProteoCure COST Action gathers more than 350 researchers and their teams (31 countries represented) from the academic, clinical, and industrial sectors, who share the conviction that our understanding of proteostasis is mature enough to develop novel and highly specific therapies based on selective tuning of protein levels. Towards this objective, the Action organizes community-building activities to foster synergies among its participants and reinforce training of the next generation of European researchers. Its ambition is to function as a knowledge-based network and a creative exchange hub on normal and pathologic proteostasis, focusing on developing innovative tools modulating the level of specific protein(s)., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)

High blood pressure is a clearly established modifiable risk factor for cardiovascular and renal disease. Although most of its adverse effects develop in adulthood, it has become clear that high BP is a lifelong problem that can manifest early in life. While few would dispute the importance of taking effective steps to identify and manage this condition in middle-aged and elderly individuals, relatively little attention has been paid to the problem of high BP in children and adolescents.Therefore, the development of actions focused on early childhood, childhood and adolescence and the investigation of the underlying causes of this epidemic are of utmost importance. There is a pressing need for comprehensive pan-European action to increase the knowledge on the prevention, diagnosis and treatment of high blood pressure in children and adolescents, the current scarcity of which impedes the development of consensus across different research fields and hinders efforts to introduce changes in clinical practice. There are some aspects that demand urgent action: the definition of hypertension, the prevalence of high BP in Europe, accurate measurement for early identification, the assessment of hypertension-mediated organ damage and the development and implementation of prevention strategies. In order to provide answers to all of these unanswered questions and challenges, a multidisciplinary network was established, maintained and funded by the European Cooperation in Science and Technology (COST) Association. COST is a funding organization for the creation of research networks known as COST Actions. In this case, the network will promote coordinated and collaborative activities on personalized preventive measures for children and adolescents across Europe. Resumen: La hipertensión arterial es un factor de riesgo cardiovascular y renal modificable. Aunque la mayoría de los resultados adversos ocurren en la edad adulta, la hipertensión arterial puede estar presente en etapas tempranas de la vida. Mientras pocos cuestionan la importancia de implementar medidas para identificar y manejar esta afección en personas adultas, se ha prestado relativamente poca atención al problema de la hipertensión arterial en niños y adolescentes.Conocer los orígenes de la hipertensión arterial es un tema que cada vez está más presente en los foros de debate. En este sentido, es absoluta la necesidad de una acción paneuropea con el fin de profundizar en los conocimientos sobre la prevención, el diagnóstico y el tratamiento de la hipertensión arterial en niños y adolescentes. En particular, existen algunas áreas urgentes de intervención tales como la definición de hipertensión, su prevalencia en Europa, la medición precisa para la identificación temprana de valores anormales, la evaluación del daño orgánico mediado por la hipertensión y cómo llevar a cabo estrategias de prevención. Con el fin de proporcionar respuestas a todas estas preguntas, la Comisión Europea ha aprobado y financiado una Asociación de Cooperación Europea en Ciencia y Tecnología (COST). La COST financia la creación de redes de investigación, que en nuestro caso promoverán actividades coordinadas y colaborativas sobre los problemas que presenta la hipertensión arterial en niños y adolescentes.

VascAgeNet is a new European network which will join forces in order to refine, harmonize and promote the vascular ageing concept. It aims to bring innovations in cardiovascular research from bench to bedside and to establish assessment of vascular ageing in clinical practice. The interdisciplinary, inter-country and intersectional approach will enable all important players at the different stages of the innovation process to come together, as recommended in the triple or quadruple helix model of innovation, in order to guarantee best solutions. This is deemed necessary in order for economic and revolutionary solutions to be fit for wide-spread clinical use, especially in low-income and inclusiveness target countries. Thus, a clear case exists for a strong collaboration between science and industry, to foster innovations and breakthroughs in vascular ageing in order to improve clinical practice and to reduce the burden of cardiovascular diseases globally.

Cardiovascular Disease (CVD) is the leading cause of morbidity and mortality worldwide, regardless of gender, ethnicity or income. Evidence that vascular age, as opposed to chronological age, is better related to the prognosis of CVD is convincing. Despite recent technological advances for the measurement of vascular ageing, unmet needs remain which currently limit the assessment of vascular ageing in routine clinical practice. These unmet needs include: (1) lack of easy-to-use, affordable techniques/devices, (2) insufficient validation in clinical settings, (3) fragmentation of expertise in few research laboratories globally, and (4) lack of investigator/research driven intervention studies and head-to-head comparisons between different measurement techniques. This paper summarises how a recently awarded European COoperation in Science and Technology (COST) Action on Vascular Ageing (VascAgeNet) will address these unmet needs. The broad aim of the COST Action VascAgeNet is to establish a network which will work to refine, harmonize and promote the use of vascular ageing biomarkers, in order to improve clinical practice and to reduce the burden of CVD globally.

VascAgeNet is a new European network which will join forces in order to refine, harmonize and promote the vascular ageing concept. It aims to bring innovations in cardiovascular research from bench to bedside and to establish assessment of vascular ageing in clinical practice. The interdisciplinary, inter-country and intersectional approach will enable all important players at the different stages of the innovation process to come together, as recommended in the triple or quadruple helix model of innovation, in order to guarantee best solutions. This is deemed necessary in order for economic and revolutionary solutions to be fit for wide-spread clinical use, especially in low-income and inclusiveness target countries. Thus, a clear case exists for a strong collaboration between science and industry, to foster innovations and breakthroughs in vascular ageing in order to improve clinical practice and to reduce the burden of cardiovascular diseases globally. [ABSTRACT FROM AUTHOR]

The EU-CardioRNA Cooperation in Science and Technology (COST) Action is a European-wide consortium established in 2018 with 31 European country members and four associate member countries to build bridges between translational researchers from academia and industry who conduct research on non-coding RNAs, cardiovascular diseases and similar research areas. EU-CardioRNA comprises four core working groups (WG1-4). In the first year since its launch, EU-CardioRNA met biannually to exchange and discuss recent findings in related fields of scientific research, with scientific sessions broadly divided up according to WG. These meetings are also an opportunity to establish interdisciplinary discussion groups, brainstorm ideas and make plans to apply for joint research grants and conduct other scientific activities, including knowledge transfer. Following its launch in Brussels in 2018, three WG meetings have taken place. The first of these in Lisbon, Portugal, the second in Istanbul, Turkey, and the most recent in Maastricht, The Netherlands. Each meeting includes a scientific session from each WG. This meeting report briefly describes the highlights and key take-home messages from each WG session in this first successful year of the EU-CardioRNA COST Action. [ABSTRACT FROM AUTHOR]

Cardiovascular Disease (CVD) is the leading cause of morbidity and mortality worldwide, regardless of gender, ethnicity or income. Evidence that vascular age, as opposed to chronological age, is better related to the prognosis of CVD is convincing. Despite recent technological advances for the measurement of vascular ageing, unmet needs remain which currently limit the assessment of vascular ageing in routine clinical practice. These unmet needs include: (1) lack of easy-to-use, affordable techniques/devices, (2) insufficient validation in clinical settings, (3) fragmentation of expertise in few research laboratories globally, and (4) lack of investigator/research driven intervention studies and head-to-head comparisons between different measurement techniques. This paper summarises how a recently awarded European COoperation in Science and Technology (COST) Action on Vascular Ageing (VascAgeNet) will address these unmet needs. The broad aim of the COST Action VascAgeNet is to establish a network which will work to refine, harmonize and promote the use of vascular ageing biomarkers, in order to improve clinical practice and to reduce the burden of CVD globally. [ABSTRACT FROM AUTHOR]

Nowadays, great emphasis is placed on the relationship between forest and water because forests are considered as substantial sources of many water ecosystem services. The aim of this paper is to analyze the stakeholder opinions towards the relationship between forests and water and the potential development of water-related payments for ecosystem services (PES) schemes. The study is developed in the context of COST Action CA15206–PESFOR-W (Forests for Water) aimed at synthesizing current knowledge about the PES schemes across Europe. The stakeholder opinions were mapped out using a structured questionnaire consisting of 20 questions divided into four thematic sections. The data were collected through an online survey. The results showed opinions of 142 stakeholders from 23 countries, mainly from Eastern Europe and the Mediterranean Basin. In order to analyze the collected data, the stakeholders were grouped in buyers, sellers, intermediaries, and knowledge providers. The survey results indicated that the most important category of water ecosystem services according to our sample of stakeholders is regulating services followed by provisioning services. Further findings pointed out the highest importance that shared values and direct changes in land management can have when designing water-related PES schemes. The role of public authorities and collective collaboration of different stakeholders, with emphasis on local and expert knowledge, are also identified as of crucial importance. The results show that stakeholder opinions can serve as a starting point when designing PES schemes. [ABSTRACT FROM AUTHOR]

The EU-CardioRNA Cooperation in Science and Technology (COST) Action is a European-wide consortium established in 2018 with 31 European country members and four associate member countries to build bridges between translational researchers from academia and industry who conduct research on non-coding RNAs, cardiovascular diseases and similar research areas. EU-CardioRNA comprises four core working groups (WG1–4). In the first year since its launch, EU-CardioRNA met biannually to exchange and discuss recent findings in related fields of scientific research, with scientific sessions broadly divided up according to WG. These meetings are also an opportunity to establish interdisciplinary discussion groups, brainstorm ideas and make plans to apply for joint research grants and conduct other scientific activities, including knowledge transfer. Following its launch in Brussels in 2018, three WG meetings have taken place. The first of these in Lisbon, Portugal, the second in Istanbul, Turkey, and the most recent in Maastricht, The Netherlands. Each meeting includes a scientific session from each WG. This meeting report briefly describes the highlights and key take-home messages from each WG session in this first successful year of the EU-CardioRNA COST Action.

Copyright of Procesamiento del Lenguaje Natural is the property of Sociedad Espanola para el Procesamiento del Lenguaje Natural and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The “stem cells” discipline represents one of the most dynamic areas in biomedicine. While adult marine/aquatic invertebrate stem cell (MISC) biology is of prime research and medical interest, studies on stem cells from organisms outside the classical vertebrate (e.g., human, mouse, and zebrafish) and invertebrate (e.g., Drosophila, Caenorhabditis) models have not been pursued vigorously. Marine/aquatic invertebrates constitute the largest biodiversity and the widest phylogenetic radiation on Earth, from morphologically simple organisms (e.g., sponges, cnidarians), to the more complex mollusks, crustaceans, echinoderms, and protochordates. These organisms contain a kaleidoscope of MISC-types that allow the production of a large number of novel bioactive-molecules, many of which are of significant potential interest for human health. MISCs further participate in aging and regeneration phenomena, including whole-body regeneration. For years, the European MISC-community has been highly fragmented and has established scarce ties with biomedical industries in an attempt to harness MISCs for human welfare. Thus, it is important to (i) consolidate the European community of researchers working on MISCs; (ii) promote and coordinate European research on MISC biology; (iii) stimulate young researchers to embark on research in MISC-biology; (iv) develop, validate, and share novel MISC tools and methodologies; (v) establish the MISC discipline as a forefront interest of biomedical disciplines, including nanobiomedicine; and (vi) establish collaborations with industries to exploit MISCs as sources of bioactive molecules. In order to fill the recognized gaps, the EC-COST Action 16203 “MARISTEM” has recently been launched. At its initial stage, the consortium unites 26 scientists from EC countries, Cooperating countries, and Near Neighbor Countries. [ABSTRACT FROM AUTHOR]

From 18 to 22 June 2017, the fifth biennial meeting of the International Society for Zinc Biology was held in conjunction with the final dissemination meeting of the Network for the Biology of Zinc (Zinc-Net) at the University of Central Lancashire, Cyprus campus. The meeting attracted over 160 participants, had 17 scientific symposia, 4 plenary speakers and 2 poster discussion sessions. In this report, we give an overview of the key themes of the meeting and some of the highlights from the scientific programme. [ABSTRACT FROM AUTHOR]